A 16-week single-blind, split-face, randomized study. Each patient served as their own
control, receiving onabotulinumtoxinA and abobotulinumtoxinA randomized to either the left or
right side of the face. Patients received intradermal BTXA injections at week 0 and
intramuscular BTXA injections at week 2. The objective is to examine the effectiveness of
intradermal botulinum toxin type A (BTXA) injection in improving skin texture and midface
lift while reducing pore size and sebum production, as well as investigate the differences in
effectiveness between onabotulinumtoxinA and abobotulinumtoxinA using intradermal and
intramuscular injection methods.